Ozempic

Adjunct to diet & exercise for the treatment of insufficiently controlled type 2 DM in adults, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes.

SC To be injected in the abdomen, thigh, or upper arm. Initially 0.25 mg once wkly. After 4 wk, dose should be increased to 0.5 mg once wkly. After at least 4 wk w/ 0.5 mg once wkly, dose can be increased to 1 mg once wkly to further improve glycaemic control.

May be taken with or without food.

Hypersensitivity.

Wkly doses >1 mg are not recommended. Should not be administered intravenously or intramuscularly. Should not be used in patients w/ type 1 DM or for the treatment of diabetic ketoacidosis. Not a substitute for insulin. Not recommended in patients w/ CHF NYHA class IV. Reports of pulmonary aspiration in patients undergoing general anaesth or deep sedation. Consider increased risk of residual gastric content due to delayed gastric emptying prior to performing procedures w/ general anaesth or deep sedation. May be associated w/ GI adverse reactions. Risk of acute pancreatitis. Caution in patients w/ history of pancreatitis. Increased risk of hypoglycaemia in combination w/ sulfonylurea or insulin. Increased risk of developing diabetic retinopathy complications in patients w/ diabetic retinopathy treated w/ insulin & semaglutide. Patients should avoid hypoglycaemia while driving & using machines when used in combination w/ sulfonylurea or insulin. Limited experience in patients w/ severe renal/hepatic impairment. Not recommended in patients w/ ESRD. Women of childbearing potential should use contraception while on treatment. Should not be used during pregnancy & breast-feeding. Should be discontinued at least 2 mth before a planned pregnancy. Safety & efficacy in childn & adolescents <18 yr have not yet been established. Limited therapeutic experience in elderly patients ≥75 yr.

Hypoglycaemia (when used w/ insulin or sulfonylurea); nausea, diarrhoea. Hypoglycaemia (when used w/ other oral antidiabetics), decreased appetite; dizziness; diabetic retinopathy complications; vomiting, abdominal pain/distension, constipation, dyspepsia, gastritis, GERD, eructation, flatulence; cholelithiasis; fatigue; increased lipase & amylase, decreased wt.

Potential to impact the absorption rate of concomitantly administered oral medicinal products. Caution in patients receiving oral medicinal products that require rapid GI absorption.

Antidiabetic Agents

A10BJ06 - semaglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.

P₁S₁S₃